Blocker for Blocker

Successful results of a new treatment for resistant prostate cancer

Svetlana Maslova, Hi-tech+

The study showed that almost half of the patients stopped the progression of the disease. Surprisingly, the new therapy also increased the sensitivity of the tumor to standard prostate cancer treatments, which indicates the potential of using the approach for all categories of patients.

Prostate cancer is successfully treated in the early stages, but over time, many patients become resistant to therapy. It was with such people who developed resistance to androgen-blocking therapy that scientists from Cedars-Sinai Medical Hospital worked. The results of the second phase of clinical trials are published on their website.

The new treatment aims to block the CD105 protein, which prevents existing drugs from binding to cancer cells. Nine volunteers received a CD105 inhibitor called carotuximab along with angdrogen blockers. Each of the participants was completely resistant to at least one of the androgen suppressors.

A drawing from an article by Smith et al. Antagonizing CD105 and androgen receptor to target stromal-epithelial interactions for clinical benefit, published in the journal Molecular Therapy – VM.

Against the background of treatment with carotuximab, scientists noted a halt in the progression of the disease in four patients. Further observations also showed that the drug increased the sensitivity of the tumor to androgen suppressors. This result was very unexpected.

If carotuximab is used in the early stages, it can increase the sensitivity of tumors to drugs and in the future will allow the patient to avoid the toxic effects of chemotherapy, the authors believe. It is planned that not all patients will receive such a preventive approach. Scientists intend to evaluate the potential effectiveness of preliminary blood tests.

Portal "Eternal youth" http://vechnayamolodost.ru